Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

also working with Ionis on antisense drugs for a range of targets including a nonalcoholic steatohepatitis (NASH) candidate that was the subject of a $300m licensing deal in April.

Latest news

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

Meanwhile Ionis and its subsidiary Akcea Therapeutics also got the thumbs up for their rare disease treatment Tegsedi(inotersen) – a decision which could see it approved in Europe before the US,
Pfizer drug gets speedy FDA review for rare heart failure complication

Another rival is Ionis with its inotersen candidate, which showed efficacy against polyneuropathy in a phase III trial reported last year. ... shares in both Alnylam and Ionis took a dive when it reported its phase III data earlier this year.
Despite FDA concerns, Akcea rare disease drug clears FDA panel

Earlier this week, Akcea, a subsidiary of Ionis, announced that it would be expanding its global early access programme (EAP) for volanesorsen to the US.
Daily Brief: Trump's America First speech, Is Europe's PRIME speeding up drug approvals?

Ionis and its subsidiary Akcea Therapeutics have received a thumbs up from an FDA Advisory Committee for their rare disease treatment Waylivra (volanesorsen).
AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH. Will acquire the US pharma group’s antisense drug in a deal valued up to $330m. ... Almost a year after giving up on a non-alcoholic steatohepatitis (NASH) drug licensed from Regulus, AstraZeneca has

More from news
Approximately 9 fully matching, plus 15 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration
Deal Watch January 2017

As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
Deal Watch August 2016

95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.
Deal Watch May 2016

This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.